AMBU-B Ambu A/S
Ambu A/S, together with its subsidiaries, researches, develops, manufactures, markets, and sells medical technology solutions in North America, Europe, and internationally. The company offers endoscopy products, including bronchoscopes, video laryngoscopes, rhinolaryngoscopes, duodenoscopes, gastroscopes, cystoscopes, ureteroscopes, and displaying and processing units; neurology products, such as EEG and EMG electrodes, EMG guided injections, and intraoperative monitoring products; and cardiology products comprising ECG electrodes. It also provides airway management and anaesthesia products, which include double and single lumen tubes, endobronchial blockers, laryngeal and face masks, breathing bags, and resuscitators. In addition, the company offers emergency care and training products, such as extrication collars and ALS and BLS training manikins, as well as mobile workstations, IOMs, and patient monitoring and diagnostics devices. Further, the company manufactures video capture solutions for OEMs in medical and defense imaging applications. Ambu A/S was founded in 1937 and is headquartered in Ballerup, Denmark.…
Industry Peers
Medical DevicesKey Statistics
About Ambu (CPH: AMBU-B)
›
Ambu (CPH: AMBU-B) is listed on Nasdaq Copenhagen, where its shares trade in DKK. It belongs to the Medical Devices industry, part of the Healthcare sector, and reports about 4,664 employees.
The shares were at 88.90 DKK on 19 November 2026, up 8.3% over 52 weeks. Its 52-week range is 56.25 DKK to 93.25 DKK: the price is 4.7% below the high and 58.0% above the low.
At a market capitalisation of 23.15B DKK, it trades at 36.7 times trailing earnings and 23.1 times forward earnings. The median trailing P/E of its 19 largest Medical Devices peers is 25.6, a premium of 43% for AMBU-B. It pays a dividend yielding 0.63% (it pays out 17% of its earnings), against a median of 2.36% among the dividend payers in that peer group.
Ambu reports return on equity of 10.3%, an operating margin of 13.2% and revenue up 16.0% year over year.
Its debt exceeds its cash by 57.00M DKK, a debt-to-equity ratio of 0.09. Its Piotroski F-score is 3 out of 9, a weak reading of its financial health. 8 analysts cover the stock, with an average rating of Hold; their mean price target of 97.66 DKK is 9.9% above the current price. The next earnings report is expected on 28 January 2027.